APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Drug Delivery Systems

Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.

Selected research

Market Structure

Global Pulmonary Drug Delivery Systems Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026192 pages

Choose your research edition.

Industry ResearchPulmonary Drug Delivery Systems Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Drug Delivery Systems Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Pulmonary Drug Delivery Systems Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Drug Delivery Systems Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Drug Delivery Systems Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.

The major players in global Pulmonary Drug Delivery Systems market include 3M, GSK, AstraZeneca, etc. The top 3 players occupy about 60% shares of the global market. Europe and North America are main markets, they occupy over 75% of the global market. Metered Dose Inhaler (MDI) is the main type, with a share over 60%. COPD is the main application, which holds a share over 50%.

This report provides an overview of the global Pulmonary Drug Delivery Systems market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Pulmonary Drug Delivery Systems and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pulmonary Drug Delivery Systems sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pulmonary Drug Delivery Systems market size, projected growth trends, production technologies, key applications, and end-use industries.

Pulmonary Drug Delivery Systems Segment by Company

3M

GSK

AstraZeneca

Cipla

Chiesi

Boehringer Ingelheim

Aptar

Novartis

Philips Respironics

Omron Healthcare

PARI

Skyepharma

CareFusion

Shanghai Huarui

Taian Character

Chia Tai Tianqing

Pulmonary Drug Delivery Systems Segment by Type

Nebulizers

Dry Powder Inhaler (DPI)

Metered Dose Inhaler (MDI)

Pulmonary Drug Delivery Systems Segment by Application

COPD

Asthma

Others

Pulmonary Drug Delivery Systems Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Drug Delivery Systems.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pulmonary Drug Delivery Systems market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pulmonary Drug Delivery Systems manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pulmonary Drug Delivery Systems in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pulmonary Drug Delivery Systems in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pulmonary Drug Delivery Systems Industry Trends Table 2. Pulmonary Drug Delivery Systems Industry Drivers Table 3. Pulmonary Drug Delivery Systems Industry Opportunities and Challenges Table 4. Pulmonary Drug Delivery Systems Industry Restraints Table 5. Global Pulmonary Drug Delivery Systems Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pulmonary Drug Delivery Systems Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pulmonary Drug Delivery Systems Sales by Manufacturers (M Units) & (2021-2026) Table 8. Global Pulmonary Drug Delivery Systems Sales Market Share by Manufacturers Table 9. Global Pulmonary Drug Delivery Systems Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Pulmonary Drug Delivery Systems Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pulmonary Drug Delivery Systems Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pulmonary Drug Delivery Systems Manufacturers, Product Type & Application Table 13. Global Pulmonary Drug Delivery Systems Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pulmonary Drug Delivery Systems by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Nebulizers Table 17. Major Manufacturers of Dry Powder Inhaler (DPI) Table 18. Major Manufacturers of Metered Dose Inhaler (MDI) Table 19. Global Pulmonary Drug Delivery Systems Sales by Type 2021 VS 2025 VS 2032 (M Units) Table 20. Global Pulmonary Drug Delivery Systems Sales by Type (2021-2026) & (M Units) Table 21. Global Pulmonary Drug Delivery Systems Sales by Type (2027-2032) & (M Units) Table 22. Global Pulmonary Drug Delivery Systems Sales Market Share by Type (2021-2026) Table 23. Global Pulmonary Drug Delivery Systems Sales Market Share by Type (2027-2032) Table 24. Global Pulmonary Drug Delivery Systems Revenue by Type 2021 VS 2025 VS 2032 (M Units) Table 25. Global Pulmonary Drug Delivery Systems Revenue by Type (2021-2026) & (M Units) Table 26. Global Pulmonary Drug Delivery Systems Revenue by Type (2027-2032) & (M Units) Table 27. Global Pulmonary Drug Delivery Systems Revenue Market Share by Type (2021-2026) Table 28. Global Pulmonary Drug Delivery Systems Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of COPD Table 30. Major Manufacturers of Asthma Table 31. Major Manufacturers of Others Table 32. Global Pulmonary Drug Delivery Systems Sales by Application 2021 VS 2025 VS 2032 (M Units) Table 33. Global Pulmonary Drug Delivery Systems Sales by Application (2021-2026) & (M Units) Table 34. Global Pulmonary Drug Delivery Systems Sales by Application (2027-2032) & (M Units) Table 35. Global Pulmonary Drug Delivery Systems Sales Market Share by Application (2021-2026) Table 36. Global Pulmonary Drug Delivery Systems Sales Market Share by Application (2027-2032) Table 37. Global Pulmonary Drug Delivery Systems Revenue by Application 2021 VS 2025 VS 2032 (M Units) Table 38. Global Pulmonary Drug Delivery Systems Revenue by Application (2021-2026) & (M Units) Table 39. Global Pulmonary Drug Delivery Systems Revenue by Application (2027-2032) & (M Units) Table 40. Global Pulmonary Drug Delivery Systems Revenue Market Share by Application (2021-2026) Table 41. Global Pulmonary Drug Delivery Systems Revenue Market Share by Application (2027-2032) Table 42. Global Pulmonary Drug Delivery Systems Sales by Region: 2021 VS 2025 VS 2032 (M Units) Table 43. Global Pulmonary Drug Delivery Systems Sales by Region (2021-2026) & (M Units) Table 44. Global Pulmonary Drug Delivery Systems Sales Market Share by Region (2021-2026) Table 45. Global Pulmonary Drug Delivery Systems Sales Forecasted by Region (2027-2032) & (M Units) Table 46. Global Pulmonary Drug Delivery Systems Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Pulmonary Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 48. North America Pulmonary Drug Delivery Systems Sales by Country (2021-2026) & (M Units) Table 49. North America Pulmonary Drug Delivery Systems Sales by Country (2027-2032) & (M Units) Table 50. Europe Pulmonary Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 51. Europe Pulmonary Drug Delivery Systems Sales by Country (2021-2026) & (M Units) Table 52. Europe Pulmonary Drug Delivery Systems Sales by Country (2027-2032) & (M Units) Table 53. Asia Pacific Pulmonary Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 54. Asia Pacific Pulmonary Drug Delivery Systems Sales by Country (2021-2026) & (M Units) Table 55. Asia Pacific Pulmonary Drug Delivery Systems Sales by Country (2027-2032) & (M Units) Table 56. South America, Middle East and Africa Pulmonary Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 57. South America, Middle East and Africa Pulmonary Drug Delivery Systems Sales by Country (2021-2026) & (M Units) Table 58. South America, Middle East and Africa Pulmonary Drug Delivery Systems Sales by Country (2027-2032) & (M Units) Table 59. Global Pulmonary Drug Delivery Systems Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Pulmonary Drug Delivery Systems Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Pulmonary Drug Delivery Systems Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Pulmonary Drug Delivery Systems Revenue Market Share by Region (2021-2026) Table 63. Global Pulmonary Drug Delivery Systems Revenue Market Share by Region (2027-2032) Table 64. 3M Company Information Table 65. 3M Business Overview Table 66. 3M Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. 3M Pulmonary Drug Delivery Systems Product Portfolio Table 68. 3M Recent Development Table 69. GSK Company Information Table 70. GSK Business Overview Table 71. GSK Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. GSK Pulmonary Drug Delivery Systems Product Portfolio Table 73. GSK Recent Development Table 74. AstraZeneca Company Information Table 75. AstraZeneca Business Overview Table 76. AstraZeneca Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. AstraZeneca Pulmonary Drug Delivery Systems Product Portfolio Table 78. AstraZeneca Recent Development Table 79. Cipla Company Information Table 80. Cipla Business Overview Table 81. Cipla Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Cipla Pulmonary Drug Delivery Systems Product Portfolio Table 83. Cipla Recent Development Table 84. Chiesi Company Information Table 85. Chiesi Business Overview Table 86. Chiesi Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Chiesi Pulmonary Drug Delivery Systems Product Portfolio Table 88. Chiesi Recent Development Table 89. Boehringer Ingelheim Company Information Table 90. Boehringer Ingelheim Business Overview Table 91. Boehringer Ingelheim Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Boehringer Ingelheim Pulmonary Drug Delivery Systems Product Portfolio Table 93. Boehringer Ingelheim Recent Development Table 94. Aptar Company Information Table 95. Aptar Business Overview Table 96. Aptar Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Aptar Pulmonary Drug Delivery Systems Product Portfolio Table 98. Aptar Recent Development Table 99. Novartis Company Information Table 100. Novartis Business Overview Table 101. Novartis Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Novartis Pulmonary Drug Delivery Systems Product Portfolio Table 103. Novartis Recent Development Table 104. Philips Respironics Company Information Table 105. Philips Respironics Business Overview Table 106. Philips Respironics Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Philips Respironics Pulmonary Drug Delivery Systems Product Portfolio Table 108. Philips Respironics Recent Development Table 109. Omron Healthcare Company Information Table 110. Omron Healthcare Business Overview Table 111. Omron Healthcare Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Omron Healthcare Pulmonary Drug Delivery Systems Product Portfolio Table 113. Omron Healthcare Recent Development Table 114. PARI Company Information Table 115. PARI Business Overview Table 116. PARI Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. PARI Pulmonary Drug Delivery Systems Product Portfolio Table 118. PARI Recent Development Table 119. Skyepharma Company Information Table 120. Skyepharma Business Overview Table 121. Skyepharma Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Skyepharma Pulmonary Drug Delivery Systems Product Portfolio Table 123. Skyepharma Recent Development Table 124. CareFusion Company Information Table 125. CareFusion Business Overview Table 126. CareFusion Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. CareFusion Pulmonary Drug Delivery Systems Product Portfolio Table 128. CareFusion Recent Development Table 129. Shanghai Huarui Company Information Table 130. Shanghai Huarui Business Overview Table 131. Shanghai Huarui Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Shanghai Huarui Pulmonary Drug Delivery Systems Product Portfolio Table 133. Shanghai Huarui Recent Development Table 134. Taian Character Company Information Table 135. Taian Character Business Overview Table 136. Taian Character Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Taian Character Pulmonary Drug Delivery Systems Product Portfolio Table 138. Taian Character Recent Development Table 139. Chia Tai Tianqing Company Information Table 140. Chia Tai Tianqing Business Overview Table 141. Chia Tai Tianqing Pulmonary Drug Delivery Systems Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Chia Tai Tianqing Pulmonary Drug Delivery Systems Product Portfolio Table 143. Chia Tai Tianqing Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. Pulmonary Drug Delivery Systems Distributors List Table 147. Pulmonary Drug Delivery Systems Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Pulmonary Drug Delivery Systems Product Image Figure 2. Global Pulmonary Drug Delivery Systems Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Drug Delivery Systems Market Size (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Drug Delivery Systems Sales (2021-2032) & (M Units) Figure 5. Global Pulmonary Drug Delivery Systems Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Pulmonary Drug Delivery Systems Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Nebulizers Image Figure 9. Dry Powder Inhaler (DPI) Image Figure 10. Metered Dose Inhaler (MDI) Image Figure 11. Global Pulmonary Drug Delivery Systems Sales by Type (2021 VS 2025 VS 2032) & (M Units) Figure 12. Global Pulmonary Drug Delivery Systems Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Pulmonary Drug Delivery Systems Sales Market Share by Type (2021-2032) Figure 14. Global Pulmonary Drug Delivery Systems Revenue by Type (2021 VS 2025 VS 2032) & (M Units) Figure 15. Global Pulmonary Drug Delivery Systems Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Pulmonary Drug Delivery Systems Revenue Market Share by Type (2021-2032) Figure 17. COPD Image Figure 18. Asthma Image Figure 19. Others Image Figure 20. Global Pulmonary Drug Delivery Systems Sales by Application (2021 VS 2025 VS 2032) & (M Units) Figure 21. Global Pulmonary Drug Delivery Systems Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Pulmonary Drug Delivery Systems Sales Market Share by Application (2021-2032) Figure 23. Global Pulmonary Drug Delivery Systems Revenue by Application (2021 VS 2025 VS 2032) & (M Units) Figure 24. Global Pulmonary Drug Delivery Systems Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Pulmonary Drug Delivery Systems Revenue Market Share by Application (2021-2032) Figure 26. North America Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 27. North America Pulmonary Drug Delivery Systems Sales Market Share by Country (2021-2032) Figure 28. U.S. Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 29. Canada Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 30. Mexico Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 31. Europe Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 32. Europe Pulmonary Drug Delivery Systems Sales Market Share by Country (2021-2032) Figure 33. Germany Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 34. France Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 35. U.K. Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 36. Italy Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 37. Netherlands Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 38. Asia Pacific Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 39. Asia Pacific Pulmonary Drug Delivery Systems Sales Market Share by Country (2021-2032) Figure 40. China Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 41. Japan Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 42. South Korea Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 43. Southeast Asia Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 44. India Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 45. Australia Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 46. South America, Middle East and Africa Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 47. South America, Middle East and Africa Pulmonary Drug Delivery Systems Sales Market Share by Country (2021-2032) Figure 48. Brazil Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 49. South Africa Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 50. Saudi Arabia Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 51. Turkey Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 52. Argentina Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 53. UAE Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 54. Egypt Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 55. Chile Pulmonary Drug Delivery Systems Sales and Growth Rate (2021-2032) & (M Units) Figure 56. Global Pulmonary Drug Delivery Systems Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Pulmonary Drug Delivery Systems Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Pulmonary Drug Delivery Systems Revenue (2021-2032) & (US$ Million) Figure 59. North America Pulmonary Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Pulmonary Drug Delivery Systems Revenue (2021-2032) & (US$ Million) Figure 61. Europe Pulmonary Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Pulmonary Drug Delivery Systems Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Pulmonary Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Pulmonary Drug Delivery Systems Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Pulmonary Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Pulmonary Drug Delivery Systems Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Pulmonary Drug Delivery Systems Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Nebulizers
  • Dry Powder Inhaler (DPI)
  • Metered Dose Inhaler (MDI)
Applications
  • COPD
  • Asthma
  • Others
Companies covered
  • 3M
  • GSK
  • AstraZeneca
  • Cipla
  • Chiesi
  • Boehringer Ingelheim
  • Aptar
  • Novartis
  • Philips Respironics
  • Omron Healthcare
  • PARI
  • Skyepharma
  • CareFusion
  • Shanghai Huarui
  • Taian Character
  • Chia Tai Tianqing

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pulmonary Drug Delivery Systems Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pulmonary Drug Delivery Systems Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pulmonary Drug Delivery Systems Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pulmonary Drug Delivery Systems Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pulmonary Drug Delivery Systems Market Dynamics
  1. 2.1 Pulmonary Drug Delivery Systems Industry Trends
  2. 2.2 Pulmonary Drug Delivery Systems Industry Drivers
  3. 2.3 Pulmonary Drug Delivery Systems Industry Opportunities and Challenges
  4. 2.4 Pulmonary Drug Delivery Systems Industry Restraints
3 Pulmonary Drug Delivery Systems Market by Manufacturers
  1. 3.1 Global Pulmonary Drug Delivery Systems Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pulmonary Drug Delivery Systems Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pulmonary Drug Delivery Systems Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pulmonary Drug Delivery Systems Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pulmonary Drug Delivery Systems Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pulmonary Drug Delivery Systems Manufacturers, Product Type & Application
  7. 3.7 Global Pulmonary Drug Delivery Systems Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pulmonary Drug Delivery Systems Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pulmonary Drug Delivery Systems Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pulmonary Drug Delivery Systems Tier 1, Tier 2, and Tier 3
4 Pulmonary Drug Delivery Systems Market by Type
  1. 4.1 Pulmonary Drug Delivery Systems Type Introduction
  2. 4.1.1 Nebulizers
  3. 4.1.2 Dry Powder Inhaler (DPI)
  4. 4.1.3 Metered Dose Inhaler (MDI)
  5. 4.2 Global Pulmonary Drug Delivery Systems Sales by Type
  6. 4.2.1 Global Pulmonary Drug Delivery Systems Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pulmonary Drug Delivery Systems Sales by Type (2021-2032)
  8. 4.2.3 Global Pulmonary Drug Delivery Systems Sales Market Share by Type (2021-2032)
  9. 4.3 Global Pulmonary Drug Delivery Systems Revenue by Type
  10. 4.3.1 Global Pulmonary Drug Delivery Systems Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pulmonary Drug Delivery Systems Revenue by Type (2021-2032)
  12. 4.3.3 Global Pulmonary Drug Delivery Systems Revenue Market Share by Type (2021-2032)
5 Pulmonary Drug Delivery Systems Market by Application
  1. 5.1 Pulmonary Drug Delivery Systems Application Introduction
  2. 5.1.1 COPD
  3. 5.1.2 Asthma
  4. 5.1.3 Others
  5. 5.2 Global Pulmonary Drug Delivery Systems Sales by Application
  6. 5.2.1 Global Pulmonary Drug Delivery Systems Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pulmonary Drug Delivery Systems Sales by Application (2021-2032)
  8. 5.2.3 Global Pulmonary Drug Delivery Systems Sales Market Share by Application (2021-2032)
  9. 5.3 Global Pulmonary Drug Delivery Systems Revenue by Application
  10. 5.3.1 Global Pulmonary Drug Delivery Systems Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pulmonary Drug Delivery Systems Revenue by Application (2021-2032)
  12. 5.3.3 Global Pulmonary Drug Delivery Systems Revenue Market Share by Application (2021-2032)
6 Global Pulmonary Drug Delivery Systems Sales by Region
  1. 6.1 Global Pulmonary Drug Delivery Systems Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pulmonary Drug Delivery Systems Sales by Region (2021-2032)
  3. 6.2.1 Global Pulmonary Drug Delivery Systems Sales by Region (2021-2026)
  4. 6.2.2 Global Pulmonary Drug Delivery Systems Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pulmonary Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pulmonary Drug Delivery Systems Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pulmonary Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pulmonary Drug Delivery Systems Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pulmonary Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pulmonary Drug Delivery Systems Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pulmonary Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pulmonary Drug Delivery Systems Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pulmonary Drug Delivery Systems Revenue by Region
  1. 7.1 Global Pulmonary Drug Delivery Systems Revenue by Region
  2. 7.1.1 Global Pulmonary Drug Delivery Systems Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pulmonary Drug Delivery Systems Revenue by Region (2021-2026)
  4. 7.1.3 Global Pulmonary Drug Delivery Systems Revenue by Region (2027-2032)
  5. 7.1.4 Global Pulmonary Drug Delivery Systems Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pulmonary Drug Delivery Systems Revenue (2021-2032)
  8. 7.2.2 North America Pulmonary Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pulmonary Drug Delivery Systems Revenue (2021-2032)
  11. 7.3.2 Europe Pulmonary Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pulmonary Drug Delivery Systems Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pulmonary Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pulmonary Drug Delivery Systems Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pulmonary Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 3M
  2. 8.1.1 3M Company Information
  3. 8.1.2 3M Business Overview
  4. 8.1.3 3M Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 3M Pulmonary Drug Delivery Systems Product Portfolio
  6. 8.1.5 3M Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GSK Pulmonary Drug Delivery Systems Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 AstraZeneca
  14. 8.3.1 AstraZeneca Company Information
  15. 8.3.2 AstraZeneca Business Overview
  16. 8.3.3 AstraZeneca Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Pulmonary Drug Delivery Systems Product Portfolio
  18. 8.3.5 AstraZeneca Recent Developments
  19. 8.4 Cipla
  20. 8.4.1 Cipla Company Information
  21. 8.4.2 Cipla Business Overview
  22. 8.4.3 Cipla Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Cipla Pulmonary Drug Delivery Systems Product Portfolio
  24. 8.4.5 Cipla Recent Developments
  25. 8.5 Chiesi
  26. 8.5.1 Chiesi Company Information
  27. 8.5.2 Chiesi Business Overview
  28. 8.5.3 Chiesi Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Chiesi Pulmonary Drug Delivery Systems Product Portfolio
  30. 8.5.5 Chiesi Recent Developments
  31. 8.6 Boehringer Ingelheim
  32. 8.6.1 Boehringer Ingelheim Company Information
  33. 8.6.2 Boehringer Ingelheim Business Overview
  34. 8.6.3 Boehringer Ingelheim Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Boehringer Ingelheim Pulmonary Drug Delivery Systems Product Portfolio
  36. 8.6.5 Boehringer Ingelheim Recent Developments
  37. 8.7 Aptar
  38. 8.7.1 Aptar Company Information
  39. 8.7.2 Aptar Business Overview
  40. 8.7.3 Aptar Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Aptar Pulmonary Drug Delivery Systems Product Portfolio
  42. 8.7.5 Aptar Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Pulmonary Drug Delivery Systems Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Philips Respironics
  50. 8.9.1 Philips Respironics Company Information
  51. 8.9.2 Philips Respironics Business Overview
  52. 8.9.3 Philips Respironics Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Philips Respironics Pulmonary Drug Delivery Systems Product Portfolio
  54. 8.9.5 Philips Respironics Recent Developments
  55. 8.10 Omron Healthcare
  56. 8.10.1 Omron Healthcare Company Information
  57. 8.10.2 Omron Healthcare Business Overview
  58. 8.10.3 Omron Healthcare Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Omron Healthcare Pulmonary Drug Delivery Systems Product Portfolio
  60. 8.10.5 Omron Healthcare Recent Developments
  61. 8.11 PARI
  62. 8.11.1 PARI Company Information
  63. 8.11.2 PARI Business Overview
  64. 8.11.3 PARI Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 PARI Pulmonary Drug Delivery Systems Product Portfolio
  66. 8.11.5 PARI Recent Developments
  67. 8.12 Skyepharma
  68. 8.12.1 Skyepharma Company Information
  69. 8.12.2 Skyepharma Business Overview
  70. 8.12.3 Skyepharma Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Skyepharma Pulmonary Drug Delivery Systems Product Portfolio
  72. 8.12.5 Skyepharma Recent Developments
  73. 8.13 CareFusion
  74. 8.13.1 CareFusion Company Information
  75. 8.13.2 CareFusion Business Overview
  76. 8.13.3 CareFusion Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 CareFusion Pulmonary Drug Delivery Systems Product Portfolio
  78. 8.13.5 CareFusion Recent Developments
  79. 8.14 Shanghai Huarui
  80. 8.14.1 Shanghai Huarui Company Information
  81. 8.14.2 Shanghai Huarui Business Overview
  82. 8.14.3 Shanghai Huarui Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Shanghai Huarui Pulmonary Drug Delivery Systems Product Portfolio
  84. 8.14.5 Shanghai Huarui Recent Developments
  85. 8.15 Taian Character
  86. 8.15.1 Taian Character Company Information
  87. 8.15.2 Taian Character Business Overview
  88. 8.15.3 Taian Character Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Taian Character Pulmonary Drug Delivery Systems Product Portfolio
  90. 8.15.5 Taian Character Recent Developments
  91. 8.16 Chia Tai Tianqing
  92. 8.16.1 Chia Tai Tianqing Company Information
  93. 8.16.2 Chia Tai Tianqing Business Overview
  94. 8.16.3 Chia Tai Tianqing Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Chia Tai Tianqing Pulmonary Drug Delivery Systems Product Portfolio
  96. 8.16.5 Chia Tai Tianqing Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pulmonary Drug Delivery Systems Value Chain Analysis
  2. 9.1.1 Pulmonary Drug Delivery Systems Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pulmonary Drug Delivery Systems Production Mode & Process
  6. 9.2 Pulmonary Drug Delivery Systems Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pulmonary Drug Delivery Systems Distributors
  9. 9.2.3 Pulmonary Drug Delivery Systems Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst